Skip to content

Saturday, October 24, 2026

Author

Dr. Nathan Pryce

Covers the biotech industry: pipelines, financing and FDA decisions.

Articles by Dr. Nathan Pryce

Biosimilars vs. Generics: Why the Two Are Not Interchangeable

Biosimilars vs. Generics: Why the Two Are Not Interchangeable

Dr. Nathan Pryce

A laboratory technician pipettes clear reagent into a microplate at a white bench under cool teal task lighting.

FDA Approves Shionogi's Xocova as First Oral COVID-19 Post-Exposure Prophylaxis

Dr. Nathan Pryce

A scientist in a white coat reviewing production data at a stainless bioreactor console under cool teal lighting.

Johnson & Johnson Lifts 2026 Outlook After $25.3 Billion Second Quarter

Dr. Nathan Pryce

An executive in a glass-walled office reviewing documents at a steel desk, laboratory equipment soft-focus behind cool white drapery of light.

What BioNTech's CEO Change Signals About Biotech Leadership Transitions

Dr. Nathan Pryce

A gloved scientist reviews batch records beside stainless-steel bioreactor panels under cool white lab light.

FDA Issues Complete Response Letter for Alvotech's Golimumab Biosimilar AVT05

Dr. Nathan Pryce

A scientist in safety glasses adjusts a bioreactor control panel, gloved hand on steel, cool white-teal light across glass vessels, no logos.

Parabilis Medicines Raises Record $670 Million Biotech IPO

Dr. Nathan Pryce